Skip to content
B
BiotechEdge
Start 14-Day Free Trial

CymaBay Therapeutics + Gilead Sciences

closed

$CBAY acquired by Gilead Sciences for $4.4B

Deal Summary

Deal Value
$4.4B
Price/Share
$32.5
Announced
Oct 9, 2023
Closed
Mar 14, 2024

Fund Positioning

1 of 20 tracked specialist biotech funds held $CBAY — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Foresite Capital1.6M$5.7MSep 2022Yes
← All biotech acquisitions